Main Industry
Biotechnology
Main Product/Service
ImmunAdd develops innovative and practical solutions for human health. We aim to harness the immune system to create next-generation immunotherapeutics for the treatment of infectious diseases and cancer. Our next-generation adjuvants provide better immun
Founded Year
2022
Unified Business No.
90379709
Status
Active
Number of Employees
15
Total Paid-in
Capital
373,600,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Dedicated to enhancing human health and well-being, ImmunAdd is a biotech pharmaceutical research and development company focused on drug design and formulation development. Our team members have accumulated years of experience in medicinal chemistry, drug formulation, drug regulations, biological animal evaluation, and clinical trials. With our specialized knowledge in drug development, we aim to address the urgent needs in drug therapy and contribute to human health. Our pipeline covers vaccine adjuvant development, new formulation development, and novel drug conjugation strategies applied in vaccines, cancer, and immunotherapies.
ImmunAdd Inc. was established in 2022 as a start-up biotechnology company from National Taiwan University, founded by Professor Pi-Hui Liang and scientists with years of experience in pharmaceutical and industrial sectors.
ImmunAdd Inc. was established in 2022 as a start-up biotechnology company from National Taiwan University, founded by Professor Pi-Hui Liang and scientists with years of experience in pharmaceutical and industrial sectors.
